Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study.

Front Immunol · 2024 · PMC11479934 · PMID 39416779

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

showed a trendp=0.061so close (0.05 < p ≤ 0.1)

FFS also showed a trend associated with a GC dose ≤ 4 mg/day (p=0.061). 3.7.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.